
Track key stocks like Vedanta, Adani Power, RailTel, and Aditya Birla Capital as major announcements drive market action today—see the…
Investors are increasingly turning to ‘safer’ MNC pharma stocks with a domestic focus at a time when the Trump administration…
Nomura’s June 2025 analysis shows Indian pharma majors like Sun Pharma, Dr. Reddy’s, Cipla, Lupin, and Zydus posting strong specialty…
Dr Reddy’s Q1FY26: Profit below estimates at 1.26%; revenue up 11.4%.
Zomato leads Nifty gainers with a 5% rally; explore full list of top market movers now!
Dr Reddy’s Laboratories announced that it has partnered with Alvotech, to co-develop, manufacture, and sell a biosimilar version of Keytruda…
Stocks to watch today, May 19: GIFT Nifty indicates a positive start for domestic indices. Here are top stocks to…
Dr Reddy’s posted consolidated net profit growth of 21 per cent year-on-year to Rs 1,587 crore during the March quarter,…
The pharma stocks in India see significant selloff after US President Donald Trump signs executive orders promoting active and faster…
Nomura recommends Buy for Dr. Reddy’s, Cipla, Lupin, Zydus amid pharma stock pressure. Check latest market trends!
Stocks to watch today, April 15: Explore the latest stock alerts: Macrotech, Reliance, Vedanta, Dr Reddy’s, and more. Check out…
Dr Reddy’s may cut 25% of its workforce, including high earners, amid cost-cutting. Learn more!
Pharma stocks are under significant selling pressure. Here is a detailed analysis on the top worries for the sector.
Empagliflozin is a SGLT-2 inhibitor and it has shown to significantly reduce the progression of kidney disease and heart failure.
Pharma stocks are down, but is this a golden buying opportunity? With India’s booming sector and low P/E stocks in…
Earlier this month, the US President said that he intends to impose a “25% or higher” levies on semiconductors and…
Pharma stocks plummet up to 10% amid looming US tariffs. Discover the impact!
Dr Reddy’s share prices dropped today as brokerages cut targets due to weak US and India performance. Explore the financial…